Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. The company's focus is on developing small molecule integrin inhibitors for the treatment of fibrotic diseases, including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and liver fibrosis. Pliant's lead product candidate, PLN-74809, is currently in Phase 2 clinical trials for the treatment of IPF. The company was founded in 2016 and is headquartered in South San Francisco, California.